Aug 04, 2023 13:04 JST

Source: Eisai

Eisai Listed for 22nd Consectutive Year In FTSE4Good Index Series, An Index for Socially Responsible Investment

TOKYO, Aug 04, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 22nd consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global environmental, social and governance (ESG) standards. Eisai received particularly high scores in "Corporate Governance", "Anti-Corruption", "Tax Transparency", "Labor Standards" and "Customer Responsibility", among others. As of the end of June 2023, 1,121 companies worldwide and 250 Japanese companies were included in the FTSE4Good Developed Index Series.

Currently, in addition to the MSCI ESG Leaders Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI Japan Empowering Women Index (WIN) and the S&P/JPX Carbon Efficient Index, which are ESG investment indices for Japanese stocks adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate concept is to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides to them, as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this concept.

For more information on our ESG initiatives, please visit www.eisai.com/sustainability/index.html.

Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120


Source: Eisai
Sectors: BioTech

Copyright ©2026 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
July 27 2026 22:50 JST
 
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
July 17 2026 23:24 JST
 
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
July 15 2026 23:18 JST
 
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
July 15 2026 22:51 JST
 
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 15 2026 22:21 JST
 
LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference(R) (AAIC(R)) 2026
July 13 2026 23:06 JST
 
Eisai to Showcase Alzheimer's Disease Portfolio with More Than 50 Presentations at the Alzheimer's Association International Conference(R) 2026 (AAIC(R))
July 02 2026 21:45 JST
 
UCL and Eisai renew partnership to accelerate treatments for neurodegenerative diseases
July 02 2026 21:01 JST
 
Eisai Announces Strategic Investment Supported by the UK Government's LSIMF
June 17 2026 12:28 JST
 
Eisai Deepens Body of Clinical Evidence for LENVIMA(R) (Lenvatinib) Across Established Indications at ASCO 2026
May 21 2026 23:23 JST
 
More Press release >>

Latest Press Release


More Latest Release >>